137 related articles for article (PubMed ID: 25629045)
1. Pharmacokinetics interaction between imatinib and genistein in rats.
Wang Z; Wang L; Xia MM; Sun W; Huang CK; Cui X; Hu GX; Lian QQ; Wang ZS
Biomed Res Int; 2015; 2015():368976. PubMed ID: 25629045
[TBL] [Abstract][Full Text] [Related]
2. The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats.
Liu XY; Xu T; Li WS; Luo J; Geng PW; Wang L; Xia MM; Chen MC; Yu L; Hu GX
Biomed Res Int; 2013; 2013():789184. PubMed ID: 24369535
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of silybin on pharmacokinetics of imatinib in vivo and in vitro.
Wang L; Wang Z; Xia MM; Wang YY; Wang HY; Hu GX
Can J Physiol Pharmacol; 2014 Nov; 92(11):961-4. PubMed ID: 25365188
[TBL] [Abstract][Full Text] [Related]
4. Single-dose, randomized crossover comparisons of different-strength imatinib mesylate formulations in healthy Korean male subjects.
Kim KA; Park SJ; Kim C; Park JY
Clin Ther; 2013 Oct; 35(10):1595-602. PubMed ID: 24060561
[TBL] [Abstract][Full Text] [Related]
5. Bioequivalence study of 400 and 100 mg imatinib film-coated tablets in healthy volunteers.
Ostrowicz A; Mikołajczak PL; Wierzbicka M; Boguradzki P
Acta Pol Pharm; 2014; 71(5):843-54. PubMed ID: 25362813
[TBL] [Abstract][Full Text] [Related]
6. Effect of St John's wort on imatinib mesylate pharmacokinetics.
Frye RF; Fitzgerald SM; Lagattuta TF; Hruska MW; Egorin MJ
Clin Pharmacol Ther; 2004 Oct; 76(4):323-9. PubMed ID: 15470331
[TBL] [Abstract][Full Text] [Related]
7. Bioequivalence study of two imatinib formulations after single-dose administration in healthy Korean male volunteers.
Jung JA; Kim N; Yang JS; Kim TE; Kim JR; Song GS; Kim H; Ko JW; Huh W
Drug Res (Stuttg); 2014 Dec; 64(12):651-5. PubMed ID: 24549963
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic Interaction Between Imatinib and Metformin in Rats.
Fan N; Du L; Guo T; Liu M; Chen X
Eur J Drug Metab Pharmacokinet; 2024 Mar; 49(2):171-179. PubMed ID: 38141154
[TBL] [Abstract][Full Text] [Related]
9. Effect of a proton pump inhibitor on the pharmacokinetics of imatinib.
Egorin MJ; Shah DD; Christner SM; Yerk MA; Komazec KA; Appleman LR; Redner RL; Miller BM; Beumer JH
Br J Clin Pharmacol; 2009 Sep; 68(3):370-4. PubMed ID: 19740393
[TBL] [Abstract][Full Text] [Related]
10. LC-MS-MS determination of imatinib and N-desmethyl imatinib in human plasma.
Zhang Y; Qiang S; Yu Z; Zhang W; Xu Z; Yang L; Wen A; Hang T
J Chromatogr Sci; 2014 Apr; 52(4):344-50. PubMed ID: 23574742
[TBL] [Abstract][Full Text] [Related]
11. Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.
Filppula AM; Tornio A; Niemi M; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2013 Sep; 94(3):383-93. PubMed ID: 23657159
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
Golabchifar AA; Rezaee S; Ghavamzadeh A; Alimoghaddam K; Dinan NM; Rouini MR
Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Cortes J; Jabbour E; Daley GQ; O'Brien S; Verstovsek S; Ferrajoli A; Koller C; Zhu Y; Statkevich P; Kantarjian H
Cancer; 2007 Sep; 110(6):1295-302. PubMed ID: 17623836
[TBL] [Abstract][Full Text] [Related]
14. Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers.
Tawbi H; Christner SM; Lin Y; Johnson M; Mowrey ET; Cherrin C; Chu E; Lee JJ; Puhalla S; Stoller R; Appleman LR; Miller BM; Beumer JH
Cancer Chemother Pharmacol; 2014 Jan; 73(1):207-11. PubMed ID: 24170263
[TBL] [Abstract][Full Text] [Related]
15. Imatinib for hepatocellular cancer--focus on pharmacokinetic/pharmacodynamic modelling and liver function.
Treiber G; Wex T; Schleyer E; Troeger U; Hosius C; Malfertheiner P
Cancer Lett; 2008 Feb; 260(1-2):146-54. PubMed ID: 18083304
[TBL] [Abstract][Full Text] [Related]
16. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers.
Parrillo-Campiglia S; Ercoli MC; Umpierrez O; Rodríguez P; Márquez S; Guarneri C; Estevez-Parrillo FT; Laurenz M; Estevez-Carrizo FE
Clin Ther; 2009 Oct; 31(10):2224-32. PubMed ID: 19922893
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
Peng B; Hayes M; Resta D; Racine-Poon A; Druker BJ; Talpaz M; Sawyers CL; Rosamilia M; Ford J; Lloyd P; Capdeville R
J Clin Oncol; 2004 Mar; 22(5):935-42. PubMed ID: 14990650
[TBL] [Abstract][Full Text] [Related]
18. The effect of grape seed and green tea extracts on the pharmacokinetics of imatinib and its main metabolite, N-desmethyl imatinib, in rats.
Darweesh RS; El-Elimat T; Zayed A; Khamis TN; Babaresh WM; Arafat T; Al Sharie AH
BMC Pharmacol Toxicol; 2020 Nov; 21(1):77. PubMed ID: 33198812
[TBL] [Abstract][Full Text] [Related]
19. Metabolism and disposition of imatinib mesylate in healthy volunteers.
Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G
Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570
[TBL] [Abstract][Full Text] [Related]
20. Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions.
Gotta V; Bouchet S; Widmer N; Schuld P; Decosterd LA; Buclin T; Mahon FX; Csajka C; Molimard M
Leuk Res; 2014 Jul; 38(7):764-72. PubMed ID: 24844604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
